1509-06-4

Basic information

• Product Name: 2',4',6'-Trihydroxy-3'-methylbutyrophenone
• Synonyms: 2',4',6'-Trihydroxy-3'-methylbutyrophenone
• CAS NO: 1509-06-4
• Molecular Formula: C₁₁H₁₄O₄
• Molecular Weight: 210.23
• Mol File: 1509-06-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 154-155 °C
• Boiling Point: 356.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• PKA: 7.77±0.50(Predicted)
• CAS DataBase Reference: 2',4',6'-Trihydroxy-3'-methylbutyrophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2',4',6'-Trihydroxy-3'-methylbutyrophenone(1509-06-4)
• EPA Substance Registry System: 2',4',6'-Trihydroxy-3'-methylbutyrophenone(1509-06-4)

Safety Data

• Hazardous Substances Data: 1509-06-4(Hazardous Substances Data)

Usage

General Description

2',4',6'-Trihydroxy-3'-methylbutyrophenone, also known as acarotene, is a natural compound found in the leaves of the plant acaroid resin. It is a phenolic derivative with three hydroxyl groups and a methylbutyrophenone side chain. Acarotene has been identified as a potent antioxidant and has been shown to exhibit anti-inflammatory and neuroprotective properties in various studies. Its antioxidant activity makes it a promising candidate for use in pharmaceutical and cosmetic products, as it can help protect against oxidative damage and promote overall skin health. Additionally, acarotene has potential applications in the food industry, as it may serve as a natural preservative or additive due to its antioxidant properties.

Upstream product

• 109-74-0 propyl cyanide 
• 88-03-9 2,4,6-trihydroxytoluene 
• 106214-18-0 3-butyryl-2,4,6-trihydroxy-5-methyl-benzoic acid methyl ester 
• 141-75-3 butyryl chloride 
• 7647-01-0 hydrogenchloride 
• 60-29-7 diethyl ether 
• 39828-33-6 2,4,6-Trihydroxy-3-methyl-benzoesaeure-methylester 
• 5556-54-7 bis(2,4,6-trihydroxyphenyl)methane 
• 621-23-8 1,2,3-trimethoxybenzene 
• 830-79-5 2,4,6-trimethoxybenzaldehyde 
• 14107-97-2 2,4,6-trimethoxytoluene 
• 108-73-6 3,5-dihydroxyphenol 
• 487-70-7 2,4,6-trihydroxybenzaldehyde 
• 6099-90-7 1,3,5-Trihydroxybenzene dihydrate 

Downstream Products

• 114-42-1 2-butyryl-6-(3-butyryl-2,4,6-trihydroxy-5-methyl-benzyl)-3,5-dihydroxy-4,4-dimethyl-cyclohexa-2,5-dienone 
• 4069-49-2 1,1'-(methylenebis(2,4,6-trihydroxy-3-methyl-5,1-phenylene))bis(butan-1-one) 
• 59902-38-4 1-(4,6-bis-benzyloxy-2-hydroxy-3-methyl-phenyl)-butan-1-one 
• 3761-64-6 flavaspiridic acid AB 
• 3773-25-9 flavaspidic acid PB 
• 478-48-8 1-4,6-dihydroxy-2-methoxy-3-methylphenylbutan-1-one 
• 59902-39-5 1-(4,6-bis-benzyloxy-2-methoxy-3-methyl-phenyl)-butan-1-one 

Relevant articles and documents

Synthetic method of pilosin B and intermediate pseudomonophenols thereof

The invention discloses a method for synthesizing pilosin B and intermediate pseudomonophenols thereof. The synthesis method of the pseudo-sheep equol comprises the step E. Step F and Step g. The synthetic method of the pilosin B provided by the invention is prepared by the following steps H, step J, preparation of the pseudomonophenols synthesized by the above method, and preparation of the pseudomonophenols synthesized by the method in step I. In step E, the novel amino protecting reagent with good reaction with the phenolic hydroxyl group is used as a protecting reagent, the phenol hydroxyl group of each intermediate in the intermediate molecule fragment a synthesis process is selectively protected, the reagent types are reduced and the use of toxic reagents such as benzyl chloride and the like is avoided.

Novel diphenylmethyl compounds having mycobacterium tuberculosis inhibitory activity

The invention relates to novel diphenylmethyl derivatives having mycobacterium tuberculosis inhibitory activity and a preparation method thereof and particularly relates novel diphenylmethyl derivatives having activity for inhibiting replicative and non-replicating mycobacterium tuberculosis and a preparation method thereof. In particular, the invention relates to compounds shown in the formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described in the specification. The invention also relates to the preparation method of the compounds and their pharmaceutical compositions and a use of the compounds in preparation of drugs for treating mycobacterium tuberculosis infection-caused diseases.

Synthesis and antibiotic activity of novel acylated phloroglucinol compounds against methicillin-resistant Staphylococcus aureus

The rise in antibiotic resistance among pathogenic microorganisms has created an imbalance in the drugs available for treatment, in part due to the slow development of new antibiotics. Cystic fibrosis (CF) patients are highly susceptible to antibiotic-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Phloroglucinols and related polyketide natural products have demonstrated antimicrobial activity against a number of Gram-positive bacteria including S. aureus. In this study, we investigated a series of acylated phloroglucinol derivatives to determine their potential as lead compounds for the design of novel therapeutics. To assess the activity of these compounds, we determined the minimum inhibitory and bactericidal concentration (MIC and MBC, respectively), the minimum biofilm inhibitory and biofilm eradication concentration (MBIC and MBEC, respectively), and evaluated hemolytic activity, as well as their interaction with clinically relevant antibiotics. Of the 12 compounds tested against MRSA and methicillin-susceptible strains, four showed MIC values ranging from 0.125 to 8 μg ml?1 and all of them were bactericidal. However, none of the compounds were able to eradicate biofilms at the concentrations tested. Three of the four did not display hemolytic activity under the conditions tested. Further studies on the interactions of these compounds with clinically relevant antibiotics showed that phlorodipropanophenone displayed synergistic activity when paired with doxycycline. Our results suggest that these acylated phloroglucinols have potential for being further investigated as antibacterial leads.